Nordea downgraded Genmab to Hold from Buy. The analyst attributes the large valuation pullback to significant revenue cuts. The firm sees a slower than expected sales ramp-up for Genmab’s lymphoma treatment Epkinly.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GMAB:
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Genmab announces EC approval of TEPKINLY for adults with R/R DLBCL
- Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
- Genmab receives European Commission approval of TEPKINLY
- AbbVie announces European Commission approval of TEPKINLY